183 related articles for article (PubMed ID: 17286554)
1. Phage passage after extended processing in small-virus-retentive filters.
Lute S; Bailey M; Combs J; Sukumar M; Brorson K
Biotechnol Appl Biochem; 2007 Jul; 47(Pt 3):141-51. PubMed ID: 17286554
[TBL] [Abstract][Full Text] [Related]
2. Normal-flow virus filtration: detection and assessment of the endpoint in bio-processing.
Bolton G; Cabatingan M; Rubino M; Lute S; Brorson K; Bailey M
Biotechnol Appl Biochem; 2005 Oct; 42(Pt 2):133-42. PubMed ID: 15901236
[TBL] [Abstract][Full Text] [Related]
3. Internal virus polarization model for virus retention by the Ultipor(®) VF Grade DV20 membrane.
Jackson NB; Bakhshayeshi M; Zydney AL; Mehta A; van Reis R; Kuriyel R
Biotechnol Prog; 2014; 30(4):856-63. PubMed ID: 24616397
[TBL] [Abstract][Full Text] [Related]
4. A consensus rating method for small virus-retentive filters. II. Method evaluation.
Brorson K; Lute S; Haque M; Martin J; Sato T; Moroe I; Morgan M; Krishnan M; Campbell J; Genest P; Parrella J; Dolan S; Martin S; Tarrach K; Levy R; ; Aranha H; Bailey M; Bender J; Carter J; Chen Q; Dowd C; Jani R; Jen D; Kidd S; Meltzer T; Remington K; Rice I; Romero C; Sato T; Jornitz M; Sekura CM; Sofer G; Specht R; Wojciechowski P
PDA J Pharm Sci Technol; 2008; 62(5):334-43. PubMed ID: 19055229
[TBL] [Abstract][Full Text] [Related]
5. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
[TBL] [Abstract][Full Text] [Related]
6. Achieving high mass-throughput of therapeutic proteins through parvovirus retentive filters.
Bolton GR; Basha J; Lacasse DP
Biotechnol Prog; 2010; 26(6):1671-7. PubMed ID: 20859931
[TBL] [Abstract][Full Text] [Related]
7. Evaluation and validation of virus removal by ultrafiltration during the production of diaspirin crosslinked haemoglobin (DCLHb).
Azari M; Boose JA; Burhop KE; Camacho T; Catarello J; Darling A; Ebeling AA; Estep TN; Pearson L; Guzder S; Herren J; Ogle K; Paine J; Rohn K; Sarajari R; Sun CS; Zhang L
Biologicals; 2000 Jun; 28(2):81-94. PubMed ID: 10885615
[TBL] [Abstract][Full Text] [Related]
8. The use of a microporous polyvinylidene fluoride (PVDF) membrane filter to separate contaminating viral particles from biologically important proteins.
Oshima KH; Evans-Strickfaden TT; Highsmith AK; Ades EW
Biologicals; 1996 Jun; 24(2):137-45. PubMed ID: 8889061
[TBL] [Abstract][Full Text] [Related]
9. Achieving a Successful Scale-Down Model and Optimized Economics through Parvovirus Filter Validation using Purified TrueSpikeTM Viruses.
De Vilmorin P; Slocum A; Jaber T; Schaefer O; Ruppach H; Genest P
PDA J Pharm Sci Technol; 2015; 69(3):440-9. PubMed ID: 26048749
[TBL] [Abstract][Full Text] [Related]
10. Filter preconditioning enables representative scaled-down modelling of filter capacity and viral clearance by mitigating the impact of virus spike impurities.
Khan NZ; Parrella JJ; Genest PW; Colman MS
Biotechnol Appl Biochem; 2009 Apr; 52(Pt 4):293-301. PubMed ID: 18844606
[TBL] [Abstract][Full Text] [Related]
11. Membrane filtration for virus removal.
Brandwein H; Aranha-Creado H
Dev Biol (Basel); 2000; 102():157-63. PubMed ID: 10794103
[TBL] [Abstract][Full Text] [Related]
12. Effect of antibody solution conditions on filter performance for virus removal filter Planova 20N.
Hongo-Hirasaki T; Komuro M; Ide S
Biotechnol Prog; 2010; 26(4):1080-7. PubMed ID: 20730765
[TBL] [Abstract][Full Text] [Related]
13. Limits in virus filtration capability? Impact of virus quality and spike level on virus removal with xenotropic murine leukemia virus.
Roush DJ; Myrold A; Burnham MS; And JV; Hughes JV
Biotechnol Prog; 2015; 31(1):135-44. PubMed ID: 25395156
[TBL] [Abstract][Full Text] [Related]
14. Robust scale-up of dead end filtration: impact of filter fouling mechanisms and flow distribution.
Laska ME; Brooks RP; Gayton M; Pujar NS
Biotechnol Bioeng; 2005 Nov; 92(3):308-20. PubMed ID: 16167331
[TBL] [Abstract][Full Text] [Related]
15. Integration of Planova filters in manufacturing processes of biologicals improve the virus safety effectively: A review of publicly available data.
Gröner A
Biotechnol Prog; 2024; 40(1):e3398. PubMed ID: 37985214
[TBL] [Abstract][Full Text] [Related]
16. Performance of a novel Viresolve NFR virus filter.
Brough H; Antoniou C; Carter J; Jakubik J; Xu Y; Lutz H
Biotechnol Prog; 2002; 18(4):782-95. PubMed ID: 12153313
[TBL] [Abstract][Full Text] [Related]
17. Impact of virus preparation quality on parvovirus filter performance.
Slocum A; Burnham M; Genest P; Venkiteshwaran A; Chen D; Hughes J
Biotechnol Bioeng; 2013 Jan; 110(1):229-39. PubMed ID: 22766979
[TBL] [Abstract][Full Text] [Related]
18. Effect of solution pH on protein transmission and membrane capacity during virus filtration.
Bakhshayeshi M; Zydney AL
Biotechnol Bioeng; 2008 May; 100(1):108-17. PubMed ID: 18080342
[TBL] [Abstract][Full Text] [Related]
19. The removal of phages T1 and PP7, and poliovirus from fluids with hollow-fiber ultrafilters with molecular weight cut-offs of 50,000, 13,000, and 6000.
Oshima KH; Evans-Strickfaden TT; Highsmith AK; Ades EW
Can J Microbiol; 1995; 41(4-5):316-22. PubMed ID: 8590412
[TBL] [Abstract][Full Text] [Related]
20. Virus removal from factor IX by filtration: validation of the integrity test and effect of manufacturing process conditions.
Roberts PL; Feldman P; Crombie D; Walker C; Lowery K
Biologicals; 2010 Mar; 38(2):303-10. PubMed ID: 20089418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
